The dysregulation of proper transcriptional control is a major cause of developmental diseases and cancers. Polycomb proteins form chromatin-modifying complexes that transcriptionally silence genome regions in higher eukaryotes. The BCL6 corepressor (BCOR) complex comprises ring finger protein 1B (RNF2/RING1B), polycomb group ring finger 1 (PCGF1), and lysine-specific demethylase 2B (KDM2B) and is uniquely recruited to nonmethylated CpG islands, where it removes histone H3K36me2 and induces repressive histone H2A monoubiquitylation. Germline BCOR mutations have been detected in patients with oculofaciocardiodental and Lenz microphthalmia syndromes, which are inherited conditions. Recently, several variants of BCOR and BCORlike 1 (BCORL1) chimeric fusion transcripts were reported in human cancers, including acute promyelocytic leukemia, bone sarcoma, and hepatocellular carcinoma. In addition, massively parallel sequencing has identified inactivating somatic BCOR and BCORL1 mutations in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia, medulloblastoma, and retinoblastoma. More importantly, patients with AML and MDS with BCOR mutations exhibit poor prognosis. This perspective highlights the detection of BCOR mutations and fusion transcripts of BCOR and BCORL1 and discusses their importance for diagnosing cancer subtypes and estimating the treatment responses of patients. Furthermore, this perspective proposes the need for additional functional studies to clarify the oncogenic mechanism by which BCOR and BCORL1 are disrupted in cancers, and how this may lead to the development of novel therapeutics. Mol Cancer Res; 12(4); 479-84. Ó2014 AACR.
Introduction
A major cause of developmental diseases and cancers is the dysregulation of proper transcriptional control, a process that is directly regulated by transcription factors, coactivators, and corepressors. Till date, several hundred transcriptional coregulators have been reported in the literature. Recently, the increased use of massively parallel sequencing techniques has expanded our knowledge on the induction of congenital diseases and cancers caused by specific gene mutations.
The BCL6 Corepressor Complex as a Repressive, Transcriptional Machinery
The BCL6 corepressor (BCOR) was originally identified in 2000 as an interacting corepressor of BCL6 (1) . This corepressor interacts with histone deacetylases and enhances BCL6-mediated transcriptional repression. Biochemical analyses identified BCOR as a complex comprising ring finger protein 2 (RFN2)/ring finger protein 1B (RING1B), polycomb group ring finger 1 (PCGF1)/nervous system polycomb 1 (NSPC1), lysine-specific demethylase 2B (KDM2B)/ F-box and leucine-rich repeat protein 10 (FBXL10), BCOR-like 1 (BCORL1), Ring 1 and YY1 binding protein (RYBP), YY1-associated factor 2 (YAF2), and S phase kinaseassociated protein 1 (SKP1; refs. [2] [3] [4] . The BCOR complex components are similar to the polycomb repressive complex 1 (PRC1) components ( Fig. 1; ref. 5 ).
The BCOR Complex Is a Distinct Subtype of PRC1
In higher eukaryotes, polycomb proteins form chromatinmodifying complexes that transcriptionally silence genome regions. Two main families of complexes, PRC1 and PRC2, are targeted to repressed, heterochromatic genome regions. Generally, PRC2 methylates histone H3 on lysine 27 (H3K27), whereas canonical PRC1 is recruited to the genome regions via H3K27me3. Subsequently, PRC1 monoubiquitylates histone H2A on lysine 119 (H2AK119) to induce transcriptional repression. A recent proteomics study led to the classification of six groups of PRC1 complexes (6) . Each of these groups was further categorized as either canonical or noncanonical PRC1 complexes. PCGF2/ MEL18 and PCGF4/BMI1 comprise the canonical PRC1 complexes, which depend on the presence of a CBX subunit.
Only canonical PRC1 complexes are targeted to H3K27me3-enriched genome regions through the CBX subunit (6) . On the other hand, the BCOR complex is categorized into a noncanonical PRC1 subgroup called PRC1.1 (6) . The BCOR complex includes the core components of PRC1, RING1B, and PCGF1 as well as histone H3 on lysine 26 (H3K36me) demethylase KDM2B ( Fig. 1; refs. [2] [3] [4] 6) .
RING1B is an ubiquitin E3 ligase that catalyzes the monoubiquitylation of H2AK119, and the binding of PCGF1 and KDM2B stimulates E3 ligase activity (7, 8) . KDM2B recruits the BCOR complex to nonmethylated CpG islands (CGI) through the ZF-CxxC DNA-binding domain of KDM2B (Fig. 1) , not through H3K27me3-dependent targeting mechanisms (4, 7) . In addition, ChIP-seq analysis of embryonic stem (ES) cells revealed that KDM2B was enriched near transcription start sites, including Hox gene loci (7) . These data were consistent with the findings that DNA methylation strongly excludes the recruitment of BCOR complex components (9) and that PCGF1 regulates Hox expression (10, 11) .
Another action of KDM2B is the specific demethylation of H3K36me2 via its jmjC domain ( Fig. 1; refs. 8, 12 ). However, KDM2B was shown to function as an oncogene by negatively regulating the expression of p15 ink4b tumorsuppressor gene via H3K36 demethylation in mouse embryonic fibroblasts and Hoxa9/Meis1-induced leukemia cells (12, 13) . In contrast, BCOR was shown to act as a growth suppressor in adult mesenchymal stem cells (MSC) isolated from a patient with oculofaciocardiodental (OFCD) syndrome because restoration of wildtype BCOR inhibited cell proliferation (14) . Although a BCOR mutation significantly increased H3K36me2 methylation in the MSCs isolated from the patient with OFCD syndrome (MSC-O), gene expression profiling could not detect any differences between gene expression at the Ink4a-arf-ink4b locus in the MSC-O cells and that in wild-type MSCs (14) .
PCGF1, another key component of the BCOR complex, is required for efficient H2AK119 monoubiquitylation (Fig. 1 ). Ross and colleagues observed a strong gain in self-renewal and a block in differentiation in lineagemarker negative (Lin À ) cells that were simultaneously depleted of Pcgf1 and Runx1 (11) . These data indicated that Pcgf1 primes hematopoietic progenitors for differentiation through H2AK119 monoubiquitylation on HoxA cluster genes, thus leading to the inhibition of HoxA transcription (11) .
Taken together, these findings indicate that the BCOR complex, a distinct subtype of PRC1, epigenetically regulates specific gene transcription.
Germline BCOR Mutations in OFCD and Lenz Microphthalmia Syndromes
OFCD syndrome is an X-linked, recessively inherited disease, and affected patients have canine teeth with extremely long roots, congenital cataracts, craniofacial defects, and cardiac disease. BCOR germline mutations were first reported in OFCD syndrome patients in 2004. Ng and colleagues reported different frameshift, deletion, and nonsense mutations in BCOR (located on Xp11.4) in seven OFCD syndrome families ( Fig. 2A , lower lane; refs. 16, 17) . In addition, p.P85L missense mutation in BCOR was identified in 2 patients with Lenz microphthalmia syndrome (16, 17) . These finding revealed BCOR as a key transcriptional regulator during early embryogenesis. This hypothesis has been underscored by findings in knockout mouse models of Figure 1 . The BCOR complex as a unique repressive, transcriptional machinery at CpG islands within transcription start sites (TSS). Nonmethylated CpG islands are used to recruit KDM2B through its CxxC domain, thus allowing H3K36me2 depletion via the KDM2b jmjC domain in these regions. RING1B monoubiquitylates histone H2A on K119, leading to the inhibition of specific transcription targets, including Hox, AP-2a, and Ink4b. LRR, leucine-rich region (7); RAWUL, RING finger-and WD40-associated ubiquitin-like domain (15) ; PUFD, PCGF Ub-like fold discriminator (15) .
early embryonic development (18) . In addition, BCOR regulates adult MSC functions through an epigenetic mechanism (14) . The transcription factor AP-2a is developmentally important for the regulation of cell growth, programmed cell death, and differentiation. In the MSC-O cells, AP-2a was significantly overexpressed consequent to disengagement of BCOR complex repression on the AP-2a promoter (14) . Moreover, BCOR mutations led to increased histone H3K36 methylation in the AP-2a promoter and decreased histone H2A ubiquitylation (14) .
Identification of BCOR-Retinoic Acid Receptor Alpha Fusion in a Variant of Acute Promyelocytic Leukemia
In 2010, our group reported the initial finding of a chimeric BCOR-RARA (retinoic acid receptor alpha) transcript in a t(X;17)(p11;q12) acute promyelocytic leukemia (APL) variant ( Fig. 2C; ref. 19 ). Functional analysis confirmed that BCOR-RARA inhibited the transcriptional response to retinoic acid and exhibited aberrant subcellular localization (19) . Typical APL is induced by t(15;17)(q22;q12) translocation, which results in promyelocytic leukemia (PML)-RARA fusion. PML-RARA exhibits double dominant-negative activities against the functions of both RARA and PML. Till date, fewer than 10 fusion partners of RARA have been identified in APL, including promyelocytic leukemia zinc finger (PLZF) and nucleophosmin (NPM). These fusion partners generally exert tumor-suppressive functions during leukemogenesis. The double dominant-negative activity of the PML-RARA fusion protein dysregulates the tumor-suppressive function of the partner protein; this seems to be one of the causes of leukemogenesis. In fact, NPM is among the most frequently mutated genes in patients with acute myeloid leukemia (AML).
Somatic BCOR Mutations in a Broad Range of Human Cancers
Since 2011, somatic BCOR mutations have been detected using whole-exome sequencing in 3.8% unselected patients with AML with normal karyotypes (CN-AML), 4.2% patients with myelodysplastic syndrome (MDS), and 7.4% patients with chronic myelomonocytic leukemia (CMML; 3A (DNMT3A) and runt-related transcription factor 1 (RUNX1) mutations were detected in 43.5% and 44.4% patients with BCOR-mutated AML, respectively (20) . Remarkably, BCOR mutations have been associated with poor prognosis in patients with CN-AML and MDS (20, 21) . In male patients with AML, BCOR mutations disrupted the single gene allele, whereas in female patients with AML, the mutations selectively targeted the functional allele because the exclusive expression of mutated BCOR was detected by cDNA-based amplicon deep sequencing (20) . Therefore, BCOR may also act as a single-hit tumor-suppressor gene in females. Targeted deep resequencing analyses of other myeloid-associated mutations revealed that in patients with MDS, somatic BCOR mutations arise after mutations in genes involved in splicing machinery or epigenetic regulation (21) . These somatic mutations were scattered throughout the BCOR coding sequence and included nonsense, frameshift, insertion/deletion, and consensus splice-site mutations ( Fig. 2A, upper lane) . However, BCOR mutations tended to accumulate on the C-terminal side of the protein, which contains critical domains that recruit the main components PCGF1/NSPC1 and KDM2B (2, 15) . Finally, frameshift or nonsense mutations in BCOR have been also reported in 9.5% patients with retinoblastoma (22) Table 1 ).
Somatic BCORL1 Mutations in Myeloid Malignancies
BCORL1 is a BCOR homolog located on Xq25-q26.1; this protein acts a transcriptional repressor and contains tandem ankyrin repeats and a C-terminal binding protein (CtBP)-interacting motif ( Fig. 2B; ref. 24 ). BCORL1 interacts with class II histone deacetylases and the CtBP corepressor through its PXDLS motif (24) . Inactivating BCORL1 mutations have also been identified in 5.8% patients with AML, 9.1% patients with AML with myelodysplasia-related changes (AML-MRC), 0.8% patients with MDS, and 1.9% patients with CMML (Table 1; refs. 21, 25) . The distribution and types of BCORL1 mutations were similar to those of BCOR mutations (Fig. 2B) ; however, the prognostic value of BCORL1 mutations remains unclear. Notably, BCORL1 depletion increased the replating capacity of Runx1-depleted Lin À cells (11) . These results suggest that BCORL1 dysregulation may be a cause of myeloid malignancy.
BCOR-Cyclin B3 Fusion in a Subtype of Bone Sarcoma
BCOR and BCORL1 are ubiquitously expressed nuclear proteins. It is not surprising that genes belonging to the BCOR family are mutated in patients with nonhematologic malignancies. Till date, two types of intrachromosomal inversions involving the BCOR family have been reported. BCOR-CCNB3 (cyclin B3) fusion was identified by RNASeq in a subtype of bone sarcoma (26) . BCOR-CCNB3 fuses exons 1 to 15 of BCOR to exons 5 to 12 of CCNB3 in an inframe manner ( Fig. 2C; ref 26) . CCNB3, located on Xp11.22, encodes testis-specific cyclin B3, a member of the highly conserved cyclin family. High CCNB3 expression was observed in a BCOR-CCNB3-positive sarcoma (26); this expression can potentially dysregulate the cell cycle and induce sarcoma proliferation. Gene expression profiling experiments revealed that this BCOR-CCNB3-positive sarcoma was biologically distinct from other sarcomas (26).
BCORL1-E74-Like Factor 4 Fusion in Hepatocellular Carcinoma
In addition, BCORL1-ELF4 (E74-like factor 4) fusion was identified in patients with hepatocellular carcinoma. This in-frame BCORL1-ELF4 fusion combined exons 1 to 11 of BCORL1 with exon 8 of ELF4 (Fig. 2C) and was generated by an intrachromosomal inversion (27) . ELF4/ myeloid elf-1 like factor (MEF) is a transcriptional activator that regulates hematopoietic and glioma stem cell functions as well as several lymphocytes and myelocytes (28, 29) . As a consequence of the chimeric fusion protein, BCORL1-ELF4 exhibited decreased repression activity compared with BCORL1 (27) . BCOR and BCORL1 Are Putative TumorSuppressor Genes We overviewed the genetic mutations that have been found in the BCOR family in a broad range of human cancers. These findings were previously undetectable because intrachromosomal rearrangements were difficult to reveal using conventional chromosomal analyses such as G-banding or standard Sanger sequencing. The increased use of massively parallel sequencing technology to screen large tumor sample series has led to the further identification of novel BCOR family gene mutations. These findings will be valuable for the diagnosis and genetics-based classification of unrecognized tumor subtypes, thus providing more beneficial information for estimating patient prognoses and treatment responses. The types of BCOR family mutations observed in cancers are generally disruptive to BCOR or BCORL1. These findings support the hypothesis that BCOR and BCORL1 are putative tumor-suppressor genes. However, further experiments are needed to prove this hypothesis.
Conclusions
The BCOR complex is a noncanonical subtype of the PRC1. However, KDM2B recruits the BCOR complex to nonmethylated CGI, rather than acting through H3K27me3-dependent targeting mechanisms. Furthermore, the BCOR complex acts as a transcriptional repressor to monoubiquitylate H2AK119 in specific promoter regions. Currently available data show that, in contrast with canonical PRC1, the BCOR complex is necessary for proper cell differentiation and proliferation. In addition to germline BCOR mutations in the OFCD syndrome, the discovery of somatic mutations and several chimeric fusion transcripts of BCOR and BCORL1 in a broad range of human cancers imply that BCOR and BCORL1 are putative tumor-suppressor genes. More importantly, BCOR mutations have been associated with poor prognosis in patients with CN-AML and MDS. Therefore, therapeutic interventions in BCOR complex signaling, including H2AK119 ubiquitylation and H3K36 demethylation, may improve the prognosis of patients with BCOR complexdysregulated cancers.
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